Document Detail


Lack of evidence for a high-affinity sarcosinamide carrier or a catecholamine carrier in Calu-1 lung-cancer cells, HT-29 colon-cancer cells, and DHF fibroblasts.
MedLine Citation:
PMID:  1280536     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have previously demonstrated that uptake of the amino acid amide sarcosinamide by the glioma cell line SK-MG-1 occurs via the catecholamine carrier that accommodates epinephrine (Km = 0.284 mM; Vmax = 0.154 nmol/10(6) cells/min). Sarcosinamide chloroethylnitrosourea (SarCNU), a new anticancer agent that exerts increased in vitro antitumor activity against gliomas as compared with BCNU (bis-chloroethylnitrosourea), the standard agent of choice, competitively inhibits sarcosinamide uptake by SK-MG-1 cells [inhibition constant (Ki) = 3.26 mM]. Using radiolabeled N-[3H]-sarcosinamide, we determined the transport of sarcosinamide in HT-29 colon-cancer cells, in Calu-1 lung-cancer cells, and in normal foreskin DHF fibroblasts. Sarcosinamide transport was linear for up to 1 min at 22 degrees C. In HT-29 cells and DHF fibroblasts, the uptake of sarcosinamide followed Michaelis-Menten kinetics of carrier-mediated transport. In HT-29 cells the Michaelis constant (Km) was 2.76 +/- 0.1 mM and the maximal velocity (Vmax) was 2.03 +/- 0.1 nmol/10(6) cells/min, whereas in DHF fibroblasts the respective values were 6.58 +/- 3.90 mM and 12.08 +/- 8.20 nmol/10(6) cells/min. In these two cell lines, neither epinephrine nor leucine significantly reduced sarcosinamide transport. In Calu-1 cells there was no evidence of carrier-mediated transport of either sarcosinamide or epinephrine. These nonglial cell lines lack a high-affinity catecholamine carrier. The increased cytotoxicity of SarCNU in gliomas may correlate with the presence of a high-affinity catecholamine carrier.
Authors:
A Malapetsa; J L Bramson; A J Noë; L C Panasci
Related Documents :
22523986 - Flexible carbon cloth electrode modified by hollow core-mesoporous shell carbon as a no...
1931436 - Relationship between pinocytic rate and uptake of transferrin by suspended rat hepatocy...
6766316 - Effects of salts and ionophores on proline transport in a moderately halopholic halotol...
15113956 - Lactobacillus casei alters hpept1-mediated glycylsarcosine uptake in caco-2 cells.
8454346 - Effects of atpase inhibitors on the response of hela cells to helicobacter pylori vacuo...
17892566 - Inorganic polyphosphate occurs in the cell wall of chlamydomonas reinhardtii and accumu...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  31     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-12-31     Completed Date:  1992-12-31     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  146-50     Citation Subset:  IM    
Affiliation:
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Transport
Colonic Neoplasms / metabolism
Drug Carriers
Epinephrine / pharmacokinetics*
Fibroblasts / metabolism
Humans
Lung Neoplasms / metabolism
Sarcosine / analogs & derivatives*,  pharmacokinetics
Tumor Cells, Cultured
Grant Support
ID/Acronym/Agency:
R01-NSC22230/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Drug Carriers; 107-97-1/Sarcosine; 51-43-4/Epinephrine; 6250-76-6/N-methylglycinamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anaesthetic implications of 32% Dextran-70 (Hyskon) during hysteroscopy: hysteroscopy syndrome.
Next Document:  Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human gra...